SOST and osteoporosis: Recent research has revealed that IGU improves disuse osteoporosis in mice by inhibiting sclerostin and the receptor activator of NF-κB ligand (RANKL) through the extracellular signal-regulated kinase/early growth response protein 1/TNF-α pathway in osteocytes (Miura et al., 2024).